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Drug-induced cardiomyopathy contributes to drug attrition. We compared two pipelines 
of predictive modeling: 1) applying elastic net (EN) to differentially expressed genes 
(DEGs) of drugs; 2) applying integer linear programming (ILP) to construct each drug’s 
signaling pathway, starting from its targets to downstream proteins, to transcription 
factors, and to its  DEGs  in human cardiomyocytes, and then  subjecting the 
genes/proteins in drugs’ signaling networks to elastic net regression. We classified 31 
drugs with availability of DEGs into 13 toxic and 18 non-toxic drugs  based on a clinical 
cardiomyopathy incidence cut-off of 0.1%. ILP-augmented modeling increased 
prediction accuracy from 79% to 88% (sensitivity: 88%; specificity: 89%) under leave-
one-out cross validation. ILP-constructed signaling networks of drugs were better 
predictors than DEGs. Per literature, the microRNAs that reportedly regulate expression 
of our 6 top predictors are of diagnostic value for natural heart failure or doxorubicin-
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Serious and life threatening drug-induced adverse events cause drug attrition at 
various stages of drug development or modification of treatment regimens. For instance, 
anthracyclines, though effective to treat cancers, are known to cause irreversible, dose-
dependent cardiotoxicity (contractility-related toxicity)1. Most recently, targeted therapy 
with tyrosine kinase inhibitors (TKIs) also cause such toxicity1.The ability to predict drug-
induced cardiotoxicity may reduce drug attrition and advance precision medicine.   
Predictive modeling of adverse drug reactions (ADRs) by integrating information 
across databases and knowledgebase of biological activities, chemistry, and ADRs has 
been undertaken2, 3, 4. However, no predictive models of drug-induced cardiomyopathy 
utilizing signaling network information have been constructed.  Harpaz et al4 stressed 
the importance of harnessing multiple sources of knowledge, biological information and 
biomedical literature for predicting drug toxicity.  In line with this notion, we reported 
herein predictive modeling by integrating prior knowledge, drug targets, and empirical 
data in order to enable the model to identify key predictors from a drug’s mode of action, 
and to have the potential to inform lead identification and development.   
  To fill in the gap, we compiled a list of 31 toxic and non-toxic drugs that were 
transcriptomically profiled in human cardiomyocytes5, 6, 7; manually curated and 
compiled their clinical incidence of treatment-related cardiomyopathy; and conducted 
predictive modeling of drug-induced cardiomyopathy. Two predictive models were 
compared: 1) applying Elastic Net (EN) to gene expression data; 2) applying integer 
linear programming (ILP) to construct  a drug’s signaling network to reflect its 
mechanism of action8, and then subjecting the nodes in individual drugs’ signaling 
networks to EN regression . The ILP formulation8 navigates a prior knowledge network 
of protein-protein, protein-TF, and TF-gene interactions, and identifies the pathways that 
connect a drug’s  targets to its DEGs.  ILP not only optimizes the solution of finding a 
drug’s signaling pathways but also enhances performance of predictive modeling by 
enabling identification of the subset of DEGs that are functionally relevant to a drug’s 
mode of action. We further referenced literature for the microRNAs, which are 
reportedly of diagnostic value for heart failure and for drug-induced cardiomyopathy as 









twell as also regulate expression of our predictors, in hopes of shedding light on 
potential microRNAs as in-vivo drug-induced cardiomyopathy biomarkers.  
 
Methods   
Compilation of drugs and their clinical incidence of drug-induced 
cardiomyopathy 
To compile the list of approved drugs that cause treatment-related 
cardiomyopathy, we referenced NIH’s Common Terminology Criteria for Adverse 
Events (CTCAE 4.03)9 and the Medical Dictionary for Regulatory Activities10 for 
cardiomyopathy-related terms to text-mine approved drug labels. The terms used 
included cardiomyopathy, heart failure, congestive heart failure, cardiac failure, left 
ventricular dysfunction, left ventricular failure, and reduction in left ventricular ejection 
fraction. The current drug label PDF files (Drugs@FDA1) were processed using a text-
mining analysis pipeline as published previously11. Individual rates of occurrence for 
cardiomyopathy were extracted by manual curation of drug labels, published redacted 
NDA reviews (Drugs@FDA), as well as published clinical studies.  
Predictive modeling 
Workflow and highlights of EN and ILP  
As shown in Figure 1, we compared two pipelines of predictive modeling. For 
Pipeline 1, we applied EN to differentially expressed genes (DEGs) of a drug.  For 
pipeline 2, we applied integer linear programming (ILP) to construct each drug’s 
signaling pathway, and then subjected the genes/proteins in each drug’s signaling 
network to EN regression.  
EN is useful for predictive modeling when predictors greatly outnumber 
observations while simultaneously being able to identify statistically significant 
predictors12.  EN regularization is useful for analyzing genomics of drug sensitivity in 
cancer13.   









tWe applied ILP to a drug’s DEGs and protein targets to model its mode of action. 
These two levels of information are connected via signal transduction where the signal 
originates at drug targets, propagates intracellularly via a complex network of signaling 
cascades, passes through the layer of transcription factors (TF), and finally reaches the 
transcriptomic level of DEGs. We modeled the interactions in the knowledge network by 
using the logic formalism14, which identified the minimum subset of the network to 
achieve the desired connectivity.  We constructed the specific signaling network for 
each drug using an ILP formulation as published previously8.  
ILP will enhance predictive performance since it has the ability to capture cellular 
responses to a drug, to identify the subset of important functional DEGs, and to help 
differentiate between compounds and translate into improved performance.    
Drug name normalization  
Drug names were first normalized and identified by the PubChem compound 
identifier to ensure consistency when downloading data from Connectivity Map15, 
DtoxS5, STITCH16, 17, and literature.    
Compilation of drug targets 
We compiled the targets of individual drugs from STITCH16, 17, and the ‘chemical-
protein links’ database and selected only human proteins. The proteins were identified 
by the SwissProt/EnsEMBL-identifier, and translated into HGNC gene symbols18 using 
the R biomaRt package, in order to match with the nodes in the prior-knowledge 
network19. We used STITCH’s ‘interaction types for links’ data file, from where we 
identified the drugs as activating or inhibiting individual target proteins. We used only 
those associating links between protein-drug pairs with an evidence score of >= 0.7.  
Gene expression data sources and handling 
Wherever data were available in Affymetrix probe IDs, the probe IDs (Affymetrix 
GeneChip Human Genome U133A Array) were translated into HUGO Gene 
Nomenclature Committee (HGNC) gene symbols18 using the biomaRt package 20 and 
hgu133a221 packages in R, an open source statistical computing graphics systems.   









tAcross all the gene lists we kept only those genes with fold change > 2 and p-value  
0.05 by a two-tailed, two-sample unequal variance Student’s t-test, adjusted separately 
for the up and down gene lists with Bonferroni correction (p-value adjusted for multiple 
comparisons) 22.  
A list of 75 drugs with drug-induced DEGs available from cancer cells15 in 
Connectivity Map (CMap) were used for exploratory modeling (See Table S1 in 
Supplementary document-CMap). To conduct robust predictive modeling, we exhausted 
literature and databases and found a list of 31 drugs of which drug-induced DEGs in 
human cardiomyocytes5 and stem cells-derived cardiomyocytes5, 6, 7 were available. The 
2 data sources for drug-induced perturbation of gene expression in cardiomyocytes 
were 1) 30 drugs from Drug Toxicity Signature Generation Center (DtoxS)5, where 
PromoCells (primary human adult cardiomyocytes) were used, and 2) literature data of 
doxorubicin studied in human stem cells-derived cardiomyocytes6, 7. The size of each 
dataset was mainly constrained by the availability of DEGs data. For DToxS data, we 
downloaded the Level 2 gene expression data, calculated the fold changes, kept only 
those DEGs with a p-value < 0.05 and a fold change > 2, and merged them from 
different donors by averaging the fold changes while excluding any DEGs with opposite 
directions of fold change among donors. 
Doxorubicin is widely studied for its dose-dependent cardiac toxicity, and is 
commonly dosed at 40mg-60 mg/m21. Following intravenous 60mg/m2, its Cmax was 
630ng/ml (1159nM) 23. See Table S2 for a few studies of transcriptomic profiles of 
doxorubicin.  For our modeling, we included the data from human-induced pluripotent 
stem cells-derived cardiomyocytes (hiPSC-CMs) by Chaudhari et al7 and Burridge et 
al6.  We included the gene expression data by Burridge et al 6 were at 100, 1000 and 
10000nM and those by Chaudhari et al7 were at 156nM (see Table S3 for the rationale).   
Identifying a drug’s mode of action using LP 
We first built a prior-knowledge network as a scaffold for constructing a drug’s  
signaling network by downloading from Reactome19 the latest version (Version 2015) of 
the “Functional interactions derived from Reactome”.  As published previously8, we 









tmerged those interactions with transcription factors and obtained a network across the 
protein, transcription factor and gene levels, which contained 64,801 reactions, 2,585 
signaling proteins and 12,376 genes.  We applied ILP to optimize a drug’s signaling 
network by providing as the input the scaffold mentioned above and its targets.  
ILP formulation was solved using IBM ILOG CPLEX optimization studio8 for the 
objective of optimizing a drug’s network. Based on the constraints that mimic signal 
transduction24 and adjustment to the specific case of very large (>10000 nodes) 
networks8, the algorithm minimized the mismatch between the data of gene expression 
measurements and the prior knowledge pathway topology.  The output was the optimal 
signaling  network of a drug, identifying the molecular interactions that appeared to be 
functional based on the input of DEGs and drug targets. We were able to select the 
minimum part of a prior-knowledge network for each drug that could explain the data in 
hand. See Supplementary document-ILP for understanding the example of 
methotrexate signaling network captured by ILP (Fig S1) and how the proposed ILP 
formulation works.  
Comparing predictive modeling by applying EN to a drug’s DEGs vs to its ILP signaling 
network  
To construct a matrix for EN regression, a drug was marked with 0 if classified as 
non-toxic and marked 1 if classified as toxic.  We classified drugs by referencing 
approved labels for the criteria of “frequent adverse events being those occurring on 
one or more occasions in at least 1/100 patients; infrequent adverse events being those 
occurring in 1/100 to 1/1000 patients; rare events being those occurring in less than 
1/1000 patients.”  Referencing the definition of rare events used in drug labeling and 
considering the distribution of clinical incidence, the number of drugs with gene 
expression data available, and the heterogeneity of clinical studies, we classified drugs 
into 2 classes, toxic for those with incidence  0.1% and non-toxic for those with 
incidence < 0.1%.  
A column of “cardiotoxicity” was created with the clinical incidence score: 1 for 
“toxic” and 0 for “non-toxic”. Each column corresponded to a single gene expressed in 









tat least one of the DEGs signatures.  Individual DEGs of a drug were assigned a value 
of 1, -1 or 0 to reflect up-regulated, down-regulated or not reported, respectively 
(pipeline 1).  The same assignments were applied to the nodes in each drug’s ILP 
signaling network (pipeline 2).   
In our modeling we used EN regression12, and more specifically a linear 
regression model with an elastic net penalty determined using the R package glmnet25. 
EN regularization is defined by two parameters, alpha and lambda. EN regression is a 
mixing of LASSO and ridge regression and combines their two penalty terms for the 
alpha parameter. When alpha equals 0, EN performs as ridge regression and when 
alpha equals 1, EN performs as LASSO.  In EN, the lambda parameter reflects 
shrinkage of the model’s coefficients. When lambda equals 0, no shrinkage of the 
model’s coefficients is performed but the coefficients decrease toward zero (though not 
exactly equal zero) as its value increases. We tried a range of values for alpha from 0 to 
1 by a 0.01 step and selected the one that minimized the mean squared error. For that 
alpha value, we selected the value of lambda that gave the minimum mean cross-
validated error.  
To validate each model, we used Leave-One-Out Cross Validation (LOOCV) by 
leaving a drug’s signature out one at a time (either DEGs or signaling network 
constructed from ILP) and did so across the whole list of drugs. Each time we calculated 
the accuracy, sensitivity and specificity for a predictive model, and selected and 
reported the model with the highest accuracy along with its precision, sensitivity and 
specificity.  From the chosen predictive model, we extracted the predictors 
(genes/proteins) that best predicted drug-induced cardiotoxicity.  The receiver operating 
characteristic (ROC) and precision-recall curves using the R package with the former 
plotted in smooth curve. 
 
Pipeline 1-applying EN to DEGs   
The results of 75 drugs with DEGs from CMap are summarized in Supplementary 
document-CMap. Among these 75 drugs with their DEGs from CMap, 24 drugs were 
toxic and the remaining 51 drugs were non-toxic.    









tA model matrix was constructed using cardiomyocyte data, with the 34 
observations (toxicity classification) as rows and 15016 variables (gene expression) as 
columns. The predictive linear model was constructed by having as input all these 
variables for EN regularization. We tried all possible different cut-off scenarios (see the 
spreadsheet ‘summary’ of Table S4 for the results of the psccm_34_gen_heart  trials 
and the detailed results of 18 models with different cut-offs in the spreadsheet ‘9’). For 
example, a cut-off of 10 meant that we ran the model by using only those genes that 
were expressed in at least 10 of the 34 signatures, meaning that the analysis started 
with 3508 genes while a cut-off of 15 started the analysis with the genes that appeared 
in at least 15 of the 34 signatures, meaning 464 genes were used as the cut-off.  
Pipeline 2 – applying EN to gene/protein nodes in ILP-constructed signaling networks   
 We first performed  exploratory modeling using a list of 75 drugs with gene 
expression data available in CMap and concluded that signaling networks of drugs 
derived from ILP outperformed their DEGs when applying EN regularization (see Figure 
S2 for ROC and precision-recall curves in Supplementary document-CMap).  
We were able to find the ILP solutions for drugs with gene expression data in 
cardiomyocytes (Table S5) except cefuroxime, domperidone, and olmesartan. These 
three drugs were removed this modeling exercise.  At the end, we had 31 signaling 
networks from 28 drugs (15 non-toxic drugs and 13 toxic drugs).  See Table S5 for the 
gene/protein nodes in the signaling network of each individual drugs. We built a model 
matrix for the 31 signaling pathways/networks by using gene expression profiles from 
cardiomyocytes and by assigning 1 if a pathway node was up-regulated, -1 if it was 
down-regulated and 0 if it was not present in a drug’s optimized signaling network.   See 
the spreadsheet ‘summary’ of Table S4 for the results of the psccm_34_ILP_heart  trial 
and the detailed results of 31 models with different cut-offs in the spreadsheet ‘10’. 
Biological context of predictors   
To gain translational insight, we searched literature for microRNAs that have 
been shown to be diagnostic markers of heart failure and also involved in regulation of 
gene expression. We mined literature and MiRTarBase, a database of experimentally-









tvalidated microRNA-target interactions 26, for a list of microRNAs, which have been 
individually reported to regulate expression of our top gene/protein predictors, and also 
been reportedly detected in the circulation of heart failure patients with a varying degree 
of severity27, 28 or of patients with doxorubicin-induced cardiomyopathy29.  
Results 
The list of drugs and toxicity profile  
The list of 31 drugs with their clinical profiles of treatment-related cardiomyopathy 
is summarized in Table 1. Literature search was also conducted to supplement clinical 
incidence of cardiomyopathy, if approved drug labels and published application reviews1 
did not have such information.  Among the 31 drugs, there were 13 toxic drugs (41.9%) 
and there were 18 non-toxic drugs (59.1%).  For those drugs without mention of 
cardiomyopathy-related toxicity described in their labels throughout the sections of 
clinical studies, post-marketing experiences, and warnings and precautions, we also 
searched literature and published reviews1 to reach the conclusion that they are non-
toxic drugs.  
Predictive modeling  
Applying EN to DEGs (pipeline 1)  
Using Leave-One-Out Cross Validation (LOOCV) across the whole list of 30 
drugs and their gene expression signatures, we achieved 79% accuracy and 75% 
precision, with 80% sensitivity and 79% specificity when using those genes that were 
expressed in at least 11 of the 34 signatures (a cut-off of 11 in spreadsheet ‘9’ of Table 
S4). The results of elastic net regularization are shown in Figure 2 (2A, 2C), and the 
genes/proteins with non-zero coefficients are PHF19, HSPA8, RIF1, CD46, MXRA7, 
RAB27A, TOMM20, MYO6 and CCNA2. ROC curves and precision-recall curves are 
shown in Figure 3 and Figure S2 of Supplementary document-CMap), respectively.    
Applying EN to the gene/protein nodes in ILP-constructed signalilng networks (pipeline 
2) 









tBy applying EN regression and LOOCV, we were able to increase both prediction 
accuracy and precision to 88%, with 88% sensitivity and 89% specificity, compared with 
the results from elastic net regression of DEGs (Table S4). EN regularization is shown 
in Figure 2 ( 2B and 2D).  The result for the psccm_34_ILP_heart  trial is in the 
spreadsheet ‘summary’ and the detailed results of 31 models with a cut-off ranging from 
1 (5012 genes/proteins in at least 1 drug) to 31 (5 genes/proteins in at least 31 network 
signatures) are in the spreadsheet ‘10’ of Table S4).  The highest accuracy, sensitivity 
and specificity were achieved at cut-off of 10 with 189 genes/proteins from at least 10 
drugs’ signaling networks. ROC and precision-recall curves are shown in Figure 3 and 
Figure S3, respectively. 
We concluded that EN-ILP (pipeline 2) outperformed EN alone (pipeline 1) when 
applied to the same set of DEGs.  
Cardiac context of top predictors 
 Using EN regularization we were able to extract the protein/gene predictors that 
best predict the toxicity classification of drug-induced cardiotoxicity (either toxic for  
0.1% clinical incidence or non-toxic for < 0.1%). The 33 protein/gene predictors along 
with their individual coefficients are summarized in Table 2. The network of the top 15 
genes/proteins selected by the model is presented on Figure 4. Cardiac relevance of 
these predictors was reviewed and summarized in Table S6.  The protein and gene 
predictors identified by EN-ILP reflected the key cellular biological factors for drug-
induced cardiotoxicity.  The EN regularization in our predictive modeling selected the 
protein/gene predictors that best predicted drug-induced cardiotoxicity. 
We mined an evidence-based database of microRNAs26 for those that reportedly 
regulate our top predictors, and also referenced literature to narrow the list to those that 
are reportedly of diagnostic value for heart failure.  Summarized in Table 3 are our top 
10 predictors and their individual regulating microRNAs that have reportedly been of 
diagnostic value for natural heart failure27, 28 or for doxorubicin-induced 
cardiomyopathy29.  
Discussion 









tWith the clinical incidence of drug-induced cardiomyopathy as a dependent 
variable, ILP-enhanced predictive modeling increased prediction accuracy from 79% to 
88%, compared to modeling with EN and DEGs alone.  This improved prediction 
signified the ability of ILP to computationally capture a drug’s mode of action through 
constructing its signaling pathways for the purpose of predictive modeling. ILP offers the 
advantage of integrating our prior knowledge of biological protein interactions and drug 
targets (Reactome, STITCH), transcription factors, and DEGs into predictive modeling. 
ILP also optimizes the size of a drug’s network signaure in addition to capturing the 
signaling pathways of a drug.  Take lapatinib as an example, it had 2265 DEGs from 
cardiomyocytes while from this set of DEGs, its ILP network consisted of 1923 nodes 
including its targets, proteins involved in its signaling transduction, transcription factors, 
and functional DEGs. 
The 33 gene/protein predictors along with their individual positive or negative 
coefficients could be used to predict ‘toxic’ or ‘non-toxic’ for a drug by linear summation 
using their individual levels of expression (either up-regulation (+) or down-regulation (-
)) from its ILP-constructed signaling network. The predictive power of this systems 
pharmacology predictive model will increase with the amount of data in the training set.  
Among the 31 drugs used to conduct predictive modeling, the distribution of toxic 
(13) vs non-toxic (18) classification was acceptable, though not ideal. Among them, 
there were 18 kinase inhibitors (17 tyrosine kinase inhibitors (TKIs) and 1 
serine/threonine kinase inhibitor), which might seemingly be off-balance from the 
perspective of the diversity of drug class.  Vemurafenib is a serine/threonine kinase 
inhibitor and not toxic.  The distribution of toxic (8) and non-toxic (9) drugs among the 
17 TKIs was acceptable. TKIs in general lack target specificity, have multiple targets, 
and were designed to disrupt the signaling pathways that are vital to cancer cell 
survival30. Unfortunately, several of these signaling pathways also play a critical role in 
cardiomyocyte biology31; consequently, several TKIs impair cardiac function. Within this 
context, our predictive modeling could be useful for predicting cardiac toxicity for future 
new chemical entities.  









tAll top 15 gene/protein predictors have relevant cardiac functions except ZNF 
823 (Supplementary Table 5). Interesting, CYP3A4 was an important predictor. Though 
CYP3A4 does not have biological interactions with other predictors, as shown in Figure 
4, it is a major drug metabolizing enzyme1. Among the 31 drugs, 10 of 13 (85%) toxic 
drugs and 11 of 18 (61%) non-toxic drugs were metabolized by CYP3A4.  The toxic 
drugs, that are primarily or extensively metabolized by CYP3A4, included amiodarone, 
axitinib, cytrabine, dasatinib, doxorubicin, imatinib, ponatinib, sorafenib, sunitinib and 
vandetanib1, 32, 33, 34. For non-toxic drugs, they are bosutinib, crizotinib, cyclosporine, 
domperidone, erlotinib, gefitinib, lapatinib, regorafenib, ruxolitinib, tofacitinib, and 
ursodeoxycholic acid1, 35.   
Some top predictors are biologically associated with focal adhesion kinase 
(FAK), a non-receptor protein-tyrosine kinase, which is involved in cytoskeleton-
associated network of signaling proteins36.  Focal adhesion complexes play a critical 
role in how cultured cardiomyocytes respond to mechanical and neurohormonal stimuli, 
and in development of heart failure37.  FAK activation plays a role in the adaptive 
response to cardiac afterload and in myocyte growth via the AKT/mTOR pathway38.  
FAK cleavage is mediated by CASP3 family during apoptosis of human normal cells39, 
and occurs with activation of EPHA2 and p38 MAPK during doxazosin-induced 
apoptosis of a cardiac cell line40.  FAK activates STAT1 during cell attachment41, and 
plays a role in cell migration with one of its actions being associated with PDGFR 
signaling complex42.  In short, the top predictors are important to maintain normal 
cardiac function. 
Per literature, some microRNAs that reportedly regulated expression of our 
predictors have also been shown to be of diagnostic value for heart failure with a 
varying degree of severity (Table 3)27, 28.  Among them, miR193-3p and miR26b-5p 
reportedly regulated more predictors than other microRNAs, and regulated 4 and 3 of 
our top predictors, respectively. It might be worthy of clinical studies to determine 
whether miR193-3p and miR26b-5p are useful in-vivo biomarkers for drug-induced 
cardiomyopathy. Literature search uncovered a recent study that investigated circulating 
microRNAs in children with anthracycline-induced acute heart injury29. Elevated miR-









t29b and miR-499 in the circulation seemed to correlate with troponin elevation in these 
children, and were identified as potential cardiomyopathy biomarkers29. This 
observation of miR-29b elevation in doxorubicin-induced cardiomyopathy differed from 
an observation of decreased expression of miR-29b-3p in the coronary sinus blood of 
heart failure patients28. MiR-29b-3p regulates expression of one of our top 10 predictors, 
PDGFRA.  Further studies are needed to investigate the role of miR-29b in drug-
induced cardiomyopathy or in natural heart failure. Even though miR-27b reportedly 
regulated CYP3A426, 43, literature search did not uncover any reports that suggested 
miR-27b be of diagnostic value for drug-induced cardiomyopathy.      
Integrating clinical incidence with the modes of action of a drug, which is depicted 
as its signaling network, for predictive modeling is a strength of our study. There are, 
however, some limitations in our approach: 1) non-toxic slightly outnumbered toxic 
drugs, 2) limitation of ILP where no biological feedback controls are considered and 
assumptions adopted in ILP formulation, 3) DEGs of doxorubicin in cardiomyocytes 
were from different sources than the rest of 30 drugs, and 4) availability of 
transcriptomic profiling data in cardiomyocytes.  Furthermore, our study inherited the 
shortcomings associated with the databases and knowledge base used for our 
modeling. The impact of disease indications on the incidence and severity of treatment-
related cardiomyopathy is not well characterized.    
Our predictive modeling of integrating clinical incidence of drug-induced 
cardiomyopathy with the signaling network of toxic and non-toxic drugs not only is 
useful for further improving its predictive power, but also identifies important 
gene/protein predictors that have relevant cardiac biological functions.  Above all, the 
top genes/protein predictors are reportedly regulated by specific microRNAs that have 
been shown to be of diagnostic value for heart failure or drug-indued cardiomyopathy.  
These predictors might be useful for shedding light on potential microRNAs as in-vivo 
biomarkers of drug-induced cardiomyopathy.  











What is the current knowledge on this topic? 
There is no translational predictive modeling that integrates a drug’s mode of action with 
clinical observation of toxicity.    
 
What question did this study answer? 
This study addresses the question of 1) how to conduct systems pharmacology 
predictive modeling that integrates the modes of action of drugs and their clinically 
observed occurrence of treatment related cardiomyopathy.     
 
What does this study add to our knowledge? 
This study adds to the knowledge of 1) the proteins/genes that are top predictors of 
drug-induced cardiomyopathy, 2) utility of drugs’ modes of action in the form of signaling 
pathways for predicting drug-induced cardiomyopathy. 
 
How might this change drug discovery, development, and/or therapeutics? 
This study enables pharmaceutical scientists to further translational systems 
pharmacology modeling to facilitate  development of therapeutics.    
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tFigure Legends  
Figure 1 Workflow of predictive modeling. We built datasets using gene expression data and we 
compared two piplelines to predict clinical drug-induced cardiomyopathy and extract features 
that best predict such toxicity. Running the Gene Expression Data at hand through a linear 
regression model with elastic net regularization or constructing signaling networks from the data 
before modeling using an ILP formulation.  
 
Figure 2 Plots of elastic net regularization results. Panels A and B show selection of the alpha 
parameter in the elastic net regularization by minimizing the leave one out cross validation 
mean squared error to extract the features (genes) that best predict clinical incidence of 
cardiomyopathy. Panels C and D show the number of variables kept in the model, with a vertical 
line showing the optimal number for maximization of accuracy. Panels A and C refer to the 
results of analyzing gene expression data only while panels B and D correspond to the results 
of analyzing drugs’ signaling networks obtained from integer linear programming formulation 
analysis. Each of the plotted lines in Figure 2C and 2D corresponds to a variable (for example a 
specific gene’s expression) and shows how its coefficient changes with the log lambda 
parameter of elastic net. The vertical line shows the optimal number of parameters kept and 
their coefficients for maximization of accuracy. 
 
Figure 3 Receiver operating characteristic (ROC) curves. Panel A: ROC curve from modeling 
DEGs using Elastic Net (EN) and panel B: ROC curve from modeling by 1) subjecting these 
DEGs to integer linear programming to construct their individual drugs’ signaling networks and 
then subject these networks to EN.    
 
 
Figure 4 Interactions among Top 15 gene/protein predictors. Interactions among the top 15 
genes/proteins selected by our model to best predict cardiomyopathy using cardiomyocytes 
data are depicted as a network using Stitch website for visualization. Small nodes correspond to 
protein of unknown 3D structure and large nodes to known or predicted. Edges represent 
protein-protein associations and the intensity of the line is proportional to the confidence score 
of each ass ciation. The confidence score is calculated by combining the probabilities from all 
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Table 1. The list of drugs with gene expression in cardiomyocytes and their 
cardiomyopathy classification 
 
Table 2. Predictors with non-zero coefficients from modeling/analysis of cardiomyocyte 
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1. Supplementary document _CMap: Supplementary documentation of Cmap data: 
Predictive modeling using  cancer cell lines data from Connectivity Map. This 
document contains Table S1 (the list of 75 drugs) and Figure S2. 
2. Supplementary document-ILP: a drug’s mode of action illustrated by ILP. This 
document contains Figure S1 (the methotrexate signaling network).  
3. Supplementary Figure S3. Panels A and B are the precision/recall curves for the 
34 differentially expressed genes modeled using Elastic Net (EN) and an  
integer linear programming-EN combination, respectively.   
4. Table S2: a few studies of transcriptomic profiles of doxorubicin 
5. Table S3: Rationale for including 4 DEGs profiles of doxorubicin  
6. Table S4: Detailed results of predictive modeling 
7. Tabel S5: ILP solutions of 34 DEGs profiles. 
8. Table S6. Biological functions of the top 15 gene/protein predictors  


















































Table 1. The list of drugs with gene expression in cardiomyocytes and their 
cardiotoxicity classification 
drug name Classification Reference* 
Afatinib   0 Drugs@FDA & literature search 
Alendronate 0 Drugs@FDA & literature search 
Amiodarone 1 Drugs@fda 
Axitinib 1 Drugs@fda 
Bosutinib   0 Drugs@FDA & literature search 
Cefuroxime 0 Drugs@FDA & literature search 
Crizotinib 0 Drugs@FDA & literature search 
Cyclosporine 0 Drugs@FDA & literature search 
Cytarabine 1 NIH DailyMed 
Dasatinib 1 Drugs@FDA 
Diclofenac  1 




Domperidone 0* Not approved by US FDA 
Doxorubicin 1 Drugs@FDA 
Diethylpropion 0 Drugs@FDA & literature search 
Erlotinib   0 “ 
Gefitinib 0 “ 
Imatinib   1 Drugs@FDA 
Lapatinib   0 Drugs@FDA; Perez et al.
53
 
Methotrexate 0 Drugs@FDA & literature search 
Olmesartan 0 Drugs@FDA & literature search 
Paroxetine 1 Drugs@FDA 
Ponatinib   1 Drugs@FDA 
Regorafenib 0 Drugs@FDA & literature search 
Ruxolitinib  0 Drugs@FDA & literature search 
Sorafenib  1 Drugs@FDA 
Sunitinib  1 “ 
Tofacitinib  0 Drugs@FDA & literature search 
Trametinib   1 “ 
Ursodeoxycholic Acid 0 Drugs@FDA & literature search 
Vandetanib 1 Drugs@FDA 
Vemurafenib 0 Drugs@FDA & literature search 
Note: toxic: 1 (clinical incidence  0.1%), non-toxic: 0 (clinical incidence <0.1%). 
https://dailymed.nlm.nih.gov/dailymed/ 
*: Domperidone was profiled by DtoxS and toxicity information was from http://www.hc-sc.gc.ca/dhp-
mps/medeff/reviews-examens/domperidone-eng.php 
 












Table 2. Predictors with non-zero coefficients from modeling/analysis of cardiomyocyte data  
Gene/protein coefficient Gene/protein coefficient Gene/protein coefficient Gene/protein coefficient 
CYP3A4 -0.39 TOP2A -0.11 FLI1 -0.03  H2AFX -0.01  
ZNF823 0.29  MAX 0.09  TCF12 -0.03  IRF1 -0.011 
CASP3 0.20  JUND -0.08 AHR 0.03  MAP3K5 0.01 
HJURP -0.19  MAPK12 -0.07  BCR 0.03  E2F1 0.01 
EPHA2 -0.19 RXRA 0.07 GATA3 0.03 SMOC2 0.01 
STAT1 -0.17 HOXA5 -0.07 SMC3 0.02  CYP2D6 -0.01 
SP2 0.15  STAT5A -0.05  EDN1 0.02     
PDGFRA -0.12  TCF7L2 0.05  FOXF2 -0.02     
TRIM28 -0.12 NR4A2 -0.03  CTCFL -0.02     
*: Nodes from drugs’ signaling networks constructed using integer linear programming (ILP) included proteins (targets and protein-protein 
interactions) and genes (differentially expressed).  The gene/protein nodes from ILP were then subjected to elastic net regularization.    
 












Table 3. Top 10 predictors and their corresponding regulating microRNAs that are reportedly of diagnostic value for heart 
failure    
Predictors Regulating microRNAs* that are of diagnostic 
value 
References 
CYP3A4 No information  
ZNF823 miR193-3p () Schulte et al 
28 
CASP3 miR-375**, miR-26b-5p(); miR-30e-5p(), let-
7a-5p () 
Schulte et al 28; Marques et al29 
HJURP miR-671-5p() Schulte et al 
28 
EPHA2 miR-26b-5p(), miR-193b-3p(); miR-16-5p() Schulte et al 
28; Marques et al 29 
STAT1 miR 145-5p () Schulte et al 
28 
SP2 miR-29a-3p (), miR-638** Schulte et al 
28 
PDGFRA miR-140-5p (); miR-26b-5p ();miR-29b-
3p();181a-5p (); miR-1233 () 
Schulte et al 28; Marques et al 29 
TRIM28 miR-423-5p (inconsistent reports), miR-193b-3p 
(), miR-183-3p (),miR-92a-3p  () 
Schulte et al 28 
TOP2A miR-193b-3p (), miR-21-5p () Schulte et al 
28, Marques et al 29 
Note: Regulating microRNAs are from Chou et al
27
 (http://mirtarbase.mbc.nctu.edu.tw); **: differentiating heart failure with reduced ejection 
fraction from heart failure with preserved ejection fraction.  and  represent elevation and decrease, respectively, compared to healthy controls. 
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